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Epidermolysis bullosa acquisita (EBA) is an antibody-mediated blistering skin disease 
associated with tissue-bound and circulating autoantibodies to type VII collagen (COL7). 
Transfer of antibodies against COL7 into mice results in a subepidermal blistering 
phenotype, strictly depending on the complement component C5. Further, activation 
predominantly by the alternative pathway is required to induce experimental EBA, as 
blistering was delayed and significantly ameliorated only in factor B−/− mice. However, 
C5 deficiency not only blocked the activation of terminal complement components and 
assembly of the membrane attack complex (MAC) but also eliminated the formation 
of C5a. Therefore, in the present study, we first aimed to elucidate which molecules 
downstream of C5 are relevant for blister formation in this EBA model and could be sub-
sequently pharmaceutically targeted. For this purpose, we injected mice deficient in C5a 
receptor 1 (C5aR1) or C6 with antibodies to murine COL7. Importantly, C5ar1−/− mice 
were significantly protected from experimental EBA, demonstrating that C5a–C5aR1 
interactions are critical intermediates linking pathogenic antibodies to tissue damage in 
this experimental model of EBA. By contrast, C6−/− mice developed widespread blistering 
disease, suggesting that MAC is dispensable for blister formation in this model. In further 
experiments, we tested the therapeutic potential of inhibitors of complement compo-
nents which were identified to play a key role in this experimental model. Complement 
components C5, factor B (fB), and C5aR1 were specifically targeted using complement 
inhibitors both prophylactically and in mice that had already developed disease. All 
complement inhibitors led to a significant improvement of the blistering phenotype when 
injected shortly before anti-COL7 antibodies. To simulate a therapeutic intervention, 
anti-fB treatment was first administered in full-blown EBA (day 5) and induced significant 
Abbreviations: COL7, type VII collagen; EBA, epidermolysis bullosa acquisita; C5aR, C5a receptor; MAC, membrane attack 
complex; fB, factor B; PD, pemphigoid diseases; IF, immunofluorescence; FcγR, Fc gamma receptor.
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inTrODUcTiOn
Pemphigoid diseases (PD), such as bullous pemphigoid (BP) and 
epidermolysis bullosa acquisita (EBA) are prototypical, antibody-
mediated autoimmune diseases of the skin. They are clinically 
characterized by (muco)-cutaneous inflammation and blistering 
and caused by autoantibodies against structural proteins of the 
skin (1–3). Tissue-bound and circulating antibodies in EBA are 
directed against the noncollagenous domain 1 of type VII colla-
gen (COL7). The pathogenic relevance of antibodies to COL7 was 
demonstrated through multiple lines of experimental evidence: 
(1) EBA autoantibodies recruit and activate leukocytes ex vivo 
and induce dermal–epidermal separation in cryosections of 
human skin (4, 5). (2) Passive transfer of antibodies to COL7 (6, 
7) and immunization with recombinant COL7 (8) in mice results 
in a blistering phenotype closely resembling human EBA.
In recent years, use of animal models has significantly con-
tributed to the understanding of PD pathogenesis. Three major 
checkpoints lead to PD: first, loss of tolerance to PD antigens 
leads to the CD4- and neutrophil-dependent generation of 
antigen-specific plasma cells. Second, autoantibodies are released 
into the circulation, where the half-life of IgG autoantibodies 
is controlled by the neonatal Fc receptor. Third, in the effector 
phase, autoantibodies bind to their target antigens located in the 
skin, which leads to the formation of a pro-inflammatory milieu 
allowing an ICAM-1- and CD18-dependent extravasation of 
myeloid effector cells into the skin. Within the skin, myeloid cells 
bind to the immune complexes via specific Fc gamma receptors 
(FcγRs), become activated, and release reactive oxygen species 
and proteases, which ultimately facilitate inflammation and 
blistering (9, 10).
Intriguingly, activation of the complement system has emerged 
as a key requirement to mediate inflammation and blistering in 
PD. Specifically, in antibody transfer models of BP and EBA, 
mice lacking the complement component C5 failed to develop 
clinically significant experimental PD (6, 11, 12). Upstream of C5, 
complement activation by both classical and alternative pathway 
is required to induce clinical manifestations. Interestingly, induc-
tion of experimental BP mainly depended on classical comple-
ment activation, whereas the alternative pathway predominantly 
drives inflammation in experimental EBA. Regarding the 
lectin-pathway, MBL-null mice developed a blistering phenotype 
similar to the wild-type control animals in experimental EBA, 
while no data has been published in this context relating to BP 
(13, 14).
C5 is cleaved by the C5 convertase into C5a and C5b fragments. 
“When C5b associates with C6 and C7, the complex inserts into cell 
membranes and interacts with C8, inducing the binding of several 
units of C9 to form a lytic pore, the terminal membrane complex 
(C5b-9, also known as the membrane attack complex, MAC). 
Many pathogens are protected from MAC-mediated lysis through 
their cell wall architecture or by employing evading strategies that 
interfere with MAC assembly. However, even sublytic amounts of 
MAC or partial complexes such as C5b-8 drive nonlethal signal-
ing events. Pro-inflammatory signaling and phagocytosis are 
essential for complement-mediated defense. During activation 
and amplification, C5a is constantly released and triggers strong 
pro-inflammatory signaling mainly through its corresponding 
G-protein-coupled receptor C5a receptor 1 (C5aR1, CD88), 
guiding neutrophils, monocytes, and macrophages toward sites 
of complement activation” [reviewed in Ref. (15)]. C5a also binds 
to the more recently discovered seven transmembrane receptor 
C5aR2 (C5L2, GPR77), which is uncoupled from G proteins (16). 
However, the exact biologic function of this C5aR is not yet fully 
determined. Depending on the experimental setting it exerts 
either decoy, regulatory or even pro-inflammatory functions 
(15, 17). Its role on EBA development has not been explored. We 
recently showed that C5aR1-deficient mice are almost completely 
protected from inflammation and blistering in antibody transfer-
induced EBA (18). It was, however, so far unclear whether the 
membrane attack complex (MAC) also contributes to skin blister-
ing in EBA, and if pharmacological targeting of complement can 
ameliorate the EBA effector phase. Current evidence suggests that 
generation of C5a and the formation of MAC are both essential 
for triggering pro-inflammatory responses in disease models like 
collagen-antibody-induced arthritis (19) and renal ischemia/
reperfusion injury (20, 21). This lack of clarity may be particularly 
relevant to the use of the C5 antibody eculizumab in PD (22). To 
address these knowledge gaps, we here systematically evaluated 
the contribution of complement components downstream of C5 
and evaluated the therapeutic potential of targeting the implicated 
complement proteins in both preventive and therapeutic settings.
MaTerials anD MeThODs
Mice
C5ar1−/− mice (n = 10) backcrossed to BALB/c mice were acquired 
from The Jackson Laboratory. C6−/− mice (n = 6) backcrossed to 
C57BL/6J mice were kindly provided by Prof. B. Paul Morgan, 
amelioration only in the final phase of disease evolution, suggesting that early intervention 
in disease development may be necessary to achieve higher efficacy. Anti-C5 treatment 
in incipient EBA (day 2) significantly ameliorated disease during the whole experiment. 
This finding is therapeutically relevant, since the humanized anti-C5 antibody eculizumab 
is already successfully used in patients. In conclusion, in this study, we have identified 
promising candidate molecules for complement-directed therapeutic intervention in EBA 
and similar autoantibody-mediated diseases.
Keywords: autoantibodies, complement, complement inhibition, immunotherapy, autoimmune diseases
FigUre 1 | C5a receptor 1 (C5aR1)-deficient mice are protected from blister induction in experimental epidermolysis bullosa acquisita. Representative day 12 
clinical pictures showing extensive skin lesions, including blisters, erosions, partly covered by crusts on the ear and front leg, and alopecia of snout and around the 
eyes in a control mouse (a), in contrast to a C5aR1-deficient mouse receiving the same dose of anti-type VII collagen (COL7) IgG (B). Immunofluorescence analysis 
revealed linear deposition of rabbit IgG (c,D) at the dermal–epidermal junction in all mice injected with anti-COL7. Deposition of murine C5 was strong in the skin of 
the control mouse (e) and weak or absent in the skin of the C5aR1-deficient mouse (F). Histological analysis of lesional murine skin revealed subepidermal cleavage 
and a neutrophil-rich inflammatory infiltrate in the skin of the control mouse (g) and to a lesser extent, in the (h) skin of the C5aR1-deficient mouse defiecient 
mouse. Affected body area of C5aR1-deficient mice vs control mice is represented as mean ± SEM. *p < 0.05 represents significant difference of disease activity 
between the two groups (i). These data were obtained from two independent experiments (n = 5/group/experiment).
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Cardiff University, UK. The C6−/− C57BL/6J mice were derived 
from a C6−/− C3H/He mouse strain lacking functional C6 (23). 
Age-matched female BALB/c and C57BL/6J mice were purchased 
from Charles River (Sulzfeld, Germany). Female mice, at 6–8 weeks 
of age, on the BALB/c background (n = 4/group), obtained from 
Charles River (Sulzfeld, Germany) were used for all complement-
blocking experiments. Anesthesia in mice was induced by inhala-
tion of isoflurane or intraperitoneal administration of a mixture 
of ketamine (100 µg/g) and xylazine (15 µg/g). The experiments 
were approved by the local authorities of the Animal Care and Use 
Committee (6/v/08) and performed by certified personnel.
affinity-Purification of antibodies
Total IgG from rabbits immunized with murine COL7c was 
purified by affinity chromatography using protein G affinity as 
previously reported and reviewed (6, 24). Before use in preclinical 
models, reactivity of IgG fractions was analyzed by immunofluo-
rescence (IF) microscopy on murine skin.
eBa induction
Passive transfer studies followed published protocols with minor 
modifications (6). Briefly, mice received six injections of 10 mg 
rabbit IgG every second day, over a period of 12  days. Skin 
affected by blisters and/or erosions was quantified as a percent-
age of the total mouse body surface area, as extensively described 
in Ref. (24). The evaluation of the affected body area was not 
performed by blinded observers. At the end of the experiment 
(day 12), mice were sacrificed and skin biopsies were taken for 
examination by histopathology and IF microscopy (to detect 
tissue-bound IgG and complement C3 deposits), as described 
(6). Deposition of murine C5 was detected by incubation of 
cryosections of perilesional skin with a monoclonal antibody 
FigUre 2 | C6-deficient mice are susceptible to inflammation and blistering in experimental epidermolysis bullosa acquisita. Skin lesions, including blisters and 
erosions covered by crusts on the ear and front leg, and alopecia of the snout and around eyes developed in both (a) C6-sufficient and (B) C6-deficient mice (day 12). 
Immunofluorescence analysis of perilesional skin revealed deposition of rabbit IgG (c,D) and murine C3 (e,F) at the dermal–epidermal junction of both C6-sufficient 
and C6-deficient mice. Histological analysis of lesional skin revealed extensive dermal–epidermal separation in both C6-sufficient (g) and C6-deficient mice (h). 
Affected body area of C6-deficient mice vs control mice is represented as mean ± SEM (i). These data were obtained from a single experiment (n = 6/group).
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specific to murine C5 (BB5.1) (25) and, finally, with a FITC-
labeled antibody specific to mouse IgG (DAKO, Glostrup, 
Denmark), as described (6).
complement inhibition
The alternative pathway of complement activation was 
inhibited by a monoclonal antibody to murine factor B (fB) 
(clone 1379) (26). For prophylactic application, mice were 
pre-injected intraperitoneally (ip) daily with 2  mg anti-fB or 
control mouse polyclonal IgG, and, subsequently, with 10 mg 
of purified anti-COL7 IgG, subcutaneously, every second day, 
for 12  days. For the therapeutic approach, mice were treated 
with six injections of 10 mg anti-COL7 IgG. Starting with day 
5, when cutaneous lesions were clearly visible in both groups, 
mice were additionally injected ip daily with anti-fB or control 
mouse IgG. For C5-inhibition, a monoclonal antibody to 
murine C5 (clone BB5.1) was used (25). In a first approach, 
mice were pre-injected ip twice a week with 40 mg/kg of anti-
C5 mAb or an isotype control (HFN7.1), and, subsequently, 
with 10 mg anti-COL7 IgG, every second day, for 12 days. For 
the therapeutic approach, mice were injected with six doses 
of pathogenic rabbit IgG. 24  h after the first anti-COL7 IgG 
injection and then twice a week (on days 4, 7, and 10) mice were 
additionally injected with anti-murine C5 or an isotype con-
trol. C5aR1 was pharmacologically targeted using a C5aR1/2 
antagonist A8Δ71–73 (C5aRA) (27). Mice were injected 
subcutaneously with 10 mg anti-COL7 IgG, every second day, 
for 12 days. One group of mice was pretreated daily with 10−5M 
C5aRA, intravenously for the first 5 days and ip for the rest of 
the experiment.
statistical analysis
Differences in disease severity were calculated using the Mann–
Whitney U-test. Means are presented ±SEM; p  <  0.05 was 
considered statistically significant.
resUlTs
c5ar1-Deficient Mice are Protected From 
induction of experimental eBa
The anaphylatoxin C5a is a powerful chemoattractant for neutro-
phils, mast cells, and monocytes, and it exerts many of its biologic 
functions exclusively by activation of C5aR1 (17). Leukocyte 
recruitment to the dermal–epidermal junction by antibodies and 
release of inflammatory mediators are prerequisites for blister 
induction in this animal model (28). To study the C5a–C5aR1 
interactions, C5ar1−/− and control mice were injected with rabbit 
antibodies to murine COL7 to induce experimental EBA. C5aR1-
deficient mice were significantly protected from blister induction 
(Figure 1), confirming that C5a–C5aR1 interactions are critical 
intermediates linking pathogenic antibodies to tissue damage in 
this experimental model of EBA.
c6-Deficient Mice are susceptible to 
induction of experimental eBa
In the skin of EBA patients, deposition of different complement 
components, including MAC, are found with an incidence ranging 
from 40 to 100%. In addition, direct IF microscopy of perilesional 
skin showed linear deposits of MAC at the dermal–epidermal junc-
tion of mice injected with antibodies to murine COL7 (6). C6 is the 
FigUre 3 | Mice pretreated with a monoclonal Ab to murine factor B (fB) develop a significantly less severe blistering phenotype. BALB/c mice were pretreated with 
anti-fB (left), followed by injection of anti-type VII collagen (COL7) IgG, and evaluated for skin lesions. To test for a potential therapeutic relevance, mice were injected 
with anti-fB in incipient disease (right). Erosions covered by crusts on the back and leg of a BALB/c mouse injected with rabbit IgG against murine COL7 (a,c). Less 
intensive lesions (alopecia) in a (B,D) BALB/c mouse challenged with the same dose of pathogenic IgG and a mAb to murine fB. Direct immunofluorescenc analysis 
of mouse skin revealed deposition of rabbit IgG in mice injected with pathogenic rabbit IgG and (e,g) control murine IgG or (F,h) anti-murine fB. Deposits of mouse 
C5 along the dermal–epidermal junction were strong in the skin of the (i,K) BALB/c mouse injected with pathogenic rabbit IgG and control murine IgG and absent in 
the skin of the (J,l) BALB/c mouse treated with antibodies to COL7and anti-murine fB. Histological analysis revealed extensive dermal–epidermal separation and 
inflammatory infiltrates, consisting mainly of neutrophils, in the skin of the control mice (M,O) and, to a lesser extent, in the skin of the treated mice (n,P). Affected 
body area of anti-fB treated vs control mice is represented as mean ± SEM. *p < 0.05 represents significant difference of disease activity between the two groups 
(Q,r). The arrow indicates the beginning of anti-fB treatment. These data were obtained from a single experiment (n = 4/group).
5
Mihai et al. Inhibition of Complement Ameliorates Blistering Disease
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 535
FigUre 4 | Anti-C5 treatment significantly ameliorates blistering in epidermolysis bullosa acquisita. BALB/c mice were pretreated with anti-C5 (left), followed by 
injection of anti-type VII collagen (COL7), and evaluated for skin lesions. Alternatively, to test for a potential therapeutic relevance, mice were injected with anti-C5 in 
incipient disease (right). Injection of rabbit anti-COL7 IgG resulted in extensive skin lesions, including blisters, erosions, partly covered by crusts on the ear and front 
leg, and alopecia around the eyes in a BALB/c mouse treated with the mock antibody (a,c). A BALB/c mouse receiving the same dose of pathogenic IgG and the 
anti-murine C5 mAb (B,D) showed less extensive lesions. Direct immunofluorescenc analysis revealed linear deposition of rabbit IgG (e, F, g, h) at the dermal–
epidermal junction in all mice injected with antibodies to COL7. Deposition of murine C5 was strong in the skin of the control mouse (i,K) and weak or absent in the 
skin of the mouse treated with anti-murine C5 antibody (J,l). Histological analysis of lesional murine skin revealed subepidermal cleavage and a neutrophil-rich 
inflammatory infiltrate in skin of the (M,O) BALB/c mouse injected with the mock antibody, and to a lesser extent, in skin of the (n,P) BALB/c mouse receiving 
antibodies to COL7and the blocking anti-C5 antibody. Affected body area of anti-murine C5 treated vs control mice is represented as mean ± SEM. *p < 0.05 
represents significant difference of disease activity between the two groups (Q, r). The arrow indicates the beginning of anti-C5 treatment. These data were 
obtained from a single experiment (n = 4/group).
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FigUre 5 | Mice pretreated with a C5a receptor (C5aR) antagonist develop less severe blistering. Skin lesions, including blisters and erosions covered by crusts on the 
ear, snout, front leg, and around eyes developed in a control mouse injected with pathogenic IgG (a). A BALB/c mouse pretreated with a C5aR antagonist and 
subsequently challenged with the same dose of antibodies to type VII collagen (COL7) showed less extensive skin lesions (B). Immunofluorescenc analysis of 
perilesional skin revealed deposition of rabbit IgG at the dermal–epidermal junction of both mice groups (c,D). Deposits of mouse C5 along the dermal–epidermal 
junction were weak in the skin of the pretreated (F) vs non-treated mouse (e). Subepidermal cleavage and neutrophil infiltration was extensive in the skin of control mice 
(g) and less present in the skin of treated mice (h), as revealed by histopathology. Affected body area of C5aRA treated vs control mice is represented as mean ± SEM. 
*p < 0.05 represents significant difference of disease activity between the two groups (i). These data were obtained from a single experiment (n = 4/group).
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first among terminal complement components that associates with 
C5b to initiate the assembly of MAC. To study the implication of 
complement in tissue destruction via C5b-9, mice deficient in C6 
and wild-type mice were injected with rabbit antibodies to murine 
COL7. Both C6-deficient and control mice developed widespread 
blistering disease (Figure  2), to a similar extent, indicating that 
MAC is dispensable for blister formation in this model.
Therapeutic complement inhibition in 
experimental eBa
In further experiments, we aimed to evaluate the efficiency of 
novel therapeutic approaches using complement inhibitors. 
To test their prophylactic potential, mice were pretreated with 
complement inhibitors and, subsequently, injected with rabbit 
antibodies to murine COL7. To test for a potential therapeutic 
relevance of complement inhibition, mice were injected with 
complement inhibitors in incipient disease.
Mice Pretreated With a Monoclonal 
antibody to Murine Factor B Develop 
less severe Blistering
We have previously demonstrated that fB-deficient mice are sig-
nificantly protected from blistering when injected with pathogenic 
antibodies to murine COL7 (14). To pharmacologically inhibit the 
alternative pathway of complement activation in this model, we 
used a blocking mAb to murine fB (clone 1379). In previous stud-
ies, this antibody prevented antiphospholipid antibody-induced 
fetal loss in a murine model dependent upon activation of the 
alternative complement pathway (26). In a first set of experiments, 
BALB/c mice were pre-injected with anti-fB or control antibody, 
and, subsequently, with anti-COL7 IgG. Mice pretreated with anti-
fB, in contrast to control mice, developed significantly less severe 
blistering throughout the whole experiment (Figure 3).
As the prophylactic application of anti-fB impaired induction 
of blistering, we next tested the potential therapeutic relevance of 
this antibody. To address this, experimental EBA was induced in 
BALB/c mice by repetitive applications of anti-COL7 IgG. On day 
5 of the experiment, when cutaneous lesions were clearly visible, 
one group of mice was additionally injected with anti-fB, while the 
other group was injected with similar amounts of control mouse 
IgG. Anti-fB treatment in incipient EBA-induced significant ame-
lioration of disease progression (Figure 3). This identifies fB as an 
additional target of therapy in inflammatory PD.
anti-c5 significantly ameliorates Blister 
Formation in Mice
We previously showed that C5-deficient mice are (almost 
completely) resistant to blister induction by transfer of anti-
COL7 IgG (6, 12). To test the prophylactic and therapeutic 
effects of C5-inhibition, we used a blocking mAb to murine 
C5 (clone BB5.1) (29). In a first approach, BALB/c mice were 
pre-injected with anti-C5 or an isotype control (HFN7.1), and, 
subsequently, with anti-COL7 IgG. In line with the experiments 
using C5-deficient mice (6), mice treated with anti-C5 developed 
8Mihai et al. Inhibition of Complement Ameliorates Blistering Disease
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significantly less blistering disease, during the whole observation 
period (Figure 4).
In a next set of experiments, we evaluated the potential thera-
peutic relevance of C5-inhibition. Based on the results obtained 
with anti-fB, we here initiated treatment at day 2 to evaluate if 
early treatment may have a more pronounced effect on inflam-
mation and blistering in experimental EBA. Anti-C5 treatment in 
incipient EBA successfully and significantly ameliorated disease 
during the entire observation period (Figure 4).
c5ar1 inhibition leads to a significant 
improvement of the Blistering Phenotype 
at the end of the Observation Period
As the experiments using C5aR1-deficient mice demonstrated 
that C5a–C5aR1 interactions are critical for blister formation in 
this model, we pharmacologically targeted the C5aR1 signaling 
using a C5aRA (27). BALB/c mice were injected with anti-COL7 
IgG for EBA induction. One group of mice was pretreated with 
the C5aRA and showed a less severe blistering phenotype com-
pared to control mice (Figure 5). These findings identify C5aR1 
as a potential drug candidate for EBA treatment.
DiscUssiOn
While the importance of C5 and mechanisms leading to C5 
cleavage in driving blistering and inflammation in PD are well 
established, relatively little was known regarding which comple-
ment components downstream of C5 cleavage are involved in this 
process. We here close this knowledge gap, confirming a major 
role of the C5a/C5aR1 axis and excluding a significant contribu-
tion of the MAC in the effector phase of EBA. The insights into 
the contribution of complement components in EBA were then 
translated into assessment of treatment in pre-clinical disease 
models. Specifically, antibodies against fB or C5 prevented onset 
of blistering and ameliorated disease progression in already 
established EBA.
Our data also add to the understanding of the complex contri-
bution of the complement system in the pathogenesis of blistering 
and inflammation in EBA. First, we highlight the predominant 
role of the C5a/C5aR1 axis, by demonstrating a pronounced ame-
lioration of the blistering phenotype in antibody transfer-induced 
EBA in mice lacking the C5aR1. These insights into C5a/C5aR1 
pathophysiology also shape out current understanding of EBA 
pathogenesis: the binding of the autoantibodies to COL7 initiates 
blistering in EBA; one of the immediate subsequent events is the 
activation of complement, which in antibody transfer-induced 
EBA occurs within 24  h after anti-COL7 IgG injection (30). 
Complement activation thus precedes the onset of blistering. 
Taking into account the effects of C5a on myeloid cells, i.e., induc-
tion of migration and activation (31), it is likely that C5a facilitates 
myeloid cell extravasation into the skin. Furthermore, “C5a can 
act as a general regulator of Fcgamma receptor (FcγR) expression 
and the C5aR1 signaling cascade seems to be important for this 
regulation, suggesting a hierarchical relationship between the 
two receptors: C5a attracts FcγR-bearing leucocytes, and C5aR 
transcriptionally regulates expression of inhibitory and activating 
FcγRs on macrophages to lower the threshold of immune complex 
activation. Recent studies also suggest the importance of direct 
cross-talk between C5aR1 and human FcγRs for progression of 
inflammatory disease, thus highlighting new aspects of this com-
plex interaction” [reviewed in Ref. (32)]. Moreover, the recently 
discovered negative feedback loop in the C5aR-FcγR cross-talk 
via dectin-1 (18) and galactosylated IgG1 Abs (33) may have 
an impact on the development of glycoengineered intravenous 
immunoglobulins (IVIG) analogous to the IVIG preparations 
administered in autoimmune diseases as an anti-inflammatory 
therapy (34). However, complement activation significantly, 
but not exclusively contributes to the formation of this pro-
inflammatory milieu and other pro-inflammatory mediators, 
such as GM-CSF (35) or IL-1β (36), could compensate for the lack 
of complement-mediated myeloid cell recruitment into the skin. 
This assumption is further supported by the observation of the 
occurrence of blistering in the absence of complement activation 
in (albeit few) outbred mice after immunization with COL7 for 
EBA induction (37).
Second, our data exclude a significant contribution of the 
MAC in the induction of inflammation and blistering in EBA. 
Previously, deposits of human IgG, murine C3, and the MAC 
were detected in the skin of mice injected with IgG antibodies 
purified from a patient with severe EBA (38). Furthermore, IgG 
antibodies from BP patients were able to fix all terminal comple-
ment components (C5–C9) resulting in MAC assembly in vitro 
(39). Hence, a contribution of the MAC to pathogenesis of blister-
ing in PD may well have been assumed. Noteworthy, C6-deficient 
mice are unable to generate functional MAC but can still form 
C5a. Therefore, our data do not exclude the possibility that MAC 
might contribute to the skin damage, but support the critical role 
of the C5a/C5aR1 axis, suggesting that skin inflammation due 
to leukocyte recruitment and activation by C5a is sufficient to 
induce blistering.
Since a number of complement-targeting compounds are 
either in clinical trials or already licensed, our findings can be 
translated into clinical practice in a relatively timely fashion. 
More specifically, the humanized anti-C5 antibody (eculizumab) 
is widely used to treat atypical hemolytic uremic syndrome and 
paroxysmal nocturnal hemoglobinuria (22). In addition, eculi-
zumab was shown to be safe and well-tolerated in a phase 1 trial in 
patients with systemic lupus erythematosus (40). These encour-
aging data suggest that anti-C5 therapy, as well as inhibition of the 
C5a–C5aR1-axis, could prevent complement-mediated injury in 
human EBA, and attenuate skin inflammation due to decreased 
leukocyte recruitment and activation by C5a. In support of this 
view, the C5aR1 antagonist CCX168 (ChemoCentryx) showed 
a significant therapeutic effect in a phase 2 study of anti-neu-
trophil cytoplasmatic antibody-associated renal vasculitis (34). 
Regarding inhibition of fB, a fragment of the anti-fB antibody 
1379 (TA106) is currently available at Taligen Therapeutics/
Alexion Pharmaceuticals, but no development intentions have 
been declared yet (34). Another inhibitor of the alternative path-
way, an mAb against factor D, lampalizumab (Roche), has been 
very recently shown to reduce geographic atrophy progression 
secondary to age-related macular degeneration (41). Yet, based 
on our findings of a superior response to preventive vs therapeutic 
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fB inhibition, we envision that complement-targeting treatments 
may be best employed to maintain the therapeutic response after 
achieving clinical remission. Furthermore, an alternative mode of 
drug application involving complement-targeting topical therapy 
could be potentially very appealing to prevent disease progres-
sion in PD. Hence, daily topical application of a purinergic P2X 
receptor antagonist inhibited complement deposition and cho-
roidal neovascularization in experimental age-related macular 
degeneration (42).
A serious drawback of (prolonged) C5-directed treatment is 
the high risk of infections. Deficiency of the terminal complement 
proteins (C5–C9) is associated with meningococcal infections, 
and all patients treated with eculizumab are vaccinated against 
Neisseria meningitidis. The selective blockade of either fB or the 
C5a/C5aR1-axis, which may even be tailored to each individual 
patient’s needs, is likely to have less side effects than blockade of 
C5. In addition, especially in BP, where activation of C5 predomi-
nantly depends on the classical pathway (13), selective blockade 
of the classical pathway through C1s inhibition (43), might prove 
useful for PD treatment.
Different models of EBA are available to mimic the clinical 
situation in patients, explore disease progression and develop new 
therapeutic approaches. The use of the antibody transfer model 
closely resembles the clinical situation and enables the examina-
tion of the effector phase of EBA. Testing therapeutic drugs or 
investigating the pathogenesis of EBA is easily performed because 
the clinical symptoms are visible within days after the IgG transfer 
(24). However, antibody transfer models are not suitable for the 
evaluation of long-term therapeutic effects (24). Recent data 
brought evidence for a xenogeneic immune reaction to rabbit 
anti-mouse COL7 IgG, a confounding effect that may contribute 
to immune complex-driven inflammation and tissue damage in 
this model, especially at later time points. Therefore, evaluation of 
results within the first 2 weeks after pathogenic antibody injection 
is recommended (44). Complex immunization-induced models 
are more suitable for the investigation of all aspects of autoimmune 
blistering diseases, including long-term therapeutic intervention 
(24). In the immunization-induced model of EBA, injection of 
mice with the immunodominant NC1 domain of COL7 leads 
to anti-COL7 autoantibody-production in most mice strains, 
whereas development of subepidermal blistering is restricted to 
certain strains. Furthermore, comparison of the autoantibody 
response in EBA-susceptible and -resistant mice showed an 
association of clinical disease with formation of complement-
fixing (IgG2) anti-COL7 antibodies (8). Hence, we emphasize 
that complement-blocking therapy may ameliorate disease 
progression in the EBA immunization-induced model. However, 
due to the dependency on complement-fixing antibodies, 
activation by the classical pathway might be more relevant in the 
immunization-model. Thus, selective blockade of the classical 
pathway might prove more useful than fB inhibition. Similar to 
the antibody transfer model, anti-C5 therapy, as well as inhibition 
of the C5a–C5aR1-axis, would probably efficiently ameliorate 
complement-mediated injury in immunization-induced EBA 
and attenuate skin inflammation due to decreased leukocyte 
recruitment and activation by C5a. However, overwhelming the 
natural tolerance against skin proteins remains challenging in 
immunization models. In addition, the effects of adjuvants during 
immunization remain largely unknown (24).
In conclusion, our study identified promising candidate mol-
ecules for complement-directed therapeutic concepts in EBA. 
Novel therapeutic agents are required in autoimmune disease, as 
treatment strategies of most antibody-mediated diseases, includ-
ing EBA, are unspecific and resume to prolonged administration 
of systemic corticosteroids and additional immunosuppressants, 
being frequently associated with severe side effects, including 
death (45). At this point, the clinically available anti-C5 antibody 
eculizumab is the most promising candidate for clinical trials in 
EBA.
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